NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Phibro Animal Health Corporation (PAHC) Stock Analysis

Phibro Animal Health Corporation (PAHC) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

PAHC

$38.25

−$0.33 (−0.86%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PAHC with… →

PAHC Key Statistics

As of Sep 4, 2026
Trading
Open
$38.26
Previous Close
$38.58
Day's Range
37.69–38.82
52-Week Range
28.25–60.08
Volume
176.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.47
Valuation
Market Cap
$1.55B
P/E Ratio
15.87
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.93
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.68
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.02
EPS (ttm)Profit attributable to each share over the last twelve months.
2.41
Financials (FY)
Revenue (FY)
$1.30B+27.37%
Net Income (FY)
$48.26M+1897.68%
Profit marginThe share of revenue left as profit after all costs and taxes.
6.57%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
21.11M
1-Year Return
−1.19%
Dividend and dates
Dividend
$0.48+1.24%
Ex-Dividend Date
September 2, 2026
Earnings Date
November 4, 2026estimated
Avg Volume
251.39K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PAHC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+3.05%
2025+80.76%
2024+86.30%
2023−10.42%
2022−32.33%
2021+7.28%
2020−20.09%
2019−21.31%
2018−3.00%
2017+15.75%
2016 (partial year)+41.86%

As of September 4, 2026.

PAHC Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$1.30B$48.26M3.7%
2024$1.02B$2.42M0.2%
2023$977.89M$32.61M3.3%
2022$942.26M$49.18M5.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.30B$399.94M$110.47M$48.26M3.7%
2024$1.02B$313.09M$53.32M$2.42M0.2%
2023$977.89M$298.24M$71.85M$32.61M3.3%
2022$942.26M$285.40M$78.99M$49.18M5.2%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

PAHC Dividend History

$0.48+0.0% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$0.363—
2025$0.484+0.0%
2024$0.484+0.0%
2023$0.484+0.0%
YearDividends per sharePaymentsChange
2026 (partial year)$0.363—
2025$0.484+0.0%
2024$0.484+0.0%
2023$0.484+0.0%
2022$0.484+0.0%
2021$0.484+0.0%
2020$0.484+0.0%
2019$0.484+14.3%
2018$0.424+5.0%
2017$0.404+300.0%
2016$0.101—

Most recent payment: $0.12 per share, ex-dividend September 2, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

PAHC Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricPAHCDrug Manufacturers - Specialty & Generic medianvs median
P/E15.8719.2718% below
P/S ratio1.022.3055% below
Profit margin6.57%−3.14%9.7 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Phibro Animal Health Corporation (PAHC) is capitalised at $1.55B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 2,605 employees.

The most recent close on file for PAHC is $38.25, dated September 4, 2026. That is −$0.33 (−0.86%) against the previous close. The 52-week range on file runs from $28.25 to $60.08. The latest close sits 35.4% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.30B. Against the prior fiscal year total of $1.02B, that is a change of +27.37%. Net income for the same year was $48.26M. That is +1,897.68% against the prior fiscal year. Profit margin runs at 6.57%. That is 9.7 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 2.41.

Across the 4 fiscal years on file, revenue moves from $942.26M in 2022 to $1.30B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

PAHC trades at a trailing price-to-earnings ratio of 15.87. That is 17.62% below the Drug Manufacturers - Specialty & Generic median of 19.27. The forward P/E on file is 9.93. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.68. The price-to-sales ratio is 1.02. On price-to-sales that is 55.45% below the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.47. Annualized volatility over the trailing 10 years is 44.52%. Over the trailing twelve months the price has returned −1.19%. Measured over 10 years, that is +6.12% a year compounded.

Growth & Income

Shareholders receive a dividend, yielding 1.24% on the latest price. That is 0.8 percentage points below the Drug Manufacturers - Specialty & Generic median yield of 2.06%. The indicated annual rate is $0.48 a share. The ex-dividend date on file is September 2, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $0.36 a share. The year before, 2025, totalled $0.48 a share.

2026 is still running; the price is +3.05% year to date. The strongest complete calendar year on file is 2024 at +86.30%; the weakest is 2022 at −32.33%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Phibro Animal Health Corporation (PAHC) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Phibro Animal Health Corporation PAHC $1.55B 15.9
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Phibro Animal Health Corporation trades at a P/E of 15.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Phibro Animal Health Corporation

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.

Visit website →